comparemela.com

Latest Breaking News On - Study group gmb - Page 1 : comparemela.com

CANKADO s Digital Health Solution Assists a New Clinical Trial, ADAPTlate

This oncologic clinical trial evaluates the efficacy and safety of the CDK 4/6 Inhibitor Abemaciclib in combination with endocrine therapy in high-risk early breast cancer patients Cologne, Germany, 07.01.2021 – CANKADO, the leading digital health application developers in Germany, assists the recently started clinical trial, ADAPTlate, organized by West German Study Group (WSG) to collect the Patient Reported Outcomes (PROs) by the CANKADO ePRO tool. The clinical trial already enrolled the first patients who are using the CANKADO e-Health system as part of the study to monitor their Quality of Life (QoL). The trial aims to gain further knowledge on the efficacy and safety of the Abemaciclib treatment in combination with endocrine therapy versus standard endocrine therapy in HR+/HER2- early breast cancer patients with high risk for disease recurrence.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.